Twist Bioscience Co. (NASDAQ:TWST) Stake Lessened by Iron Triangle Partners LP

Iron Triangle Partners LP lowered its stake in Twist Bioscience Co. (NASDAQ:TWST) by 3.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 492,471 shares of the company’s stock after selling 17,529 shares during the period. Twist Bioscience accounts for approximately 2.5% of Iron Triangle Partners LP’s holdings, making the stock its 16th biggest holding. Iron Triangle Partners LP owned 0.83% of Twist Bioscience worth $22,885,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of TWST. Van ECK Associates Corp increased its stake in Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in Twist Bioscience in the third quarter worth about $34,000. Banque Transatlantique SA acquired a new position in Twist Bioscience in the fourth quarter valued at approximately $43,000. US Bancorp DE grew its holdings in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after purchasing an additional 601 shares during the last quarter. Finally, KBC Group NV raised its position in shares of Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock worth $137,000 after purchasing an additional 1,226 shares during the period.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Robert W. Baird lowered their price objective on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a research note on Tuesday, May 6th. The Goldman Sachs Group dropped their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Tuesday, May 6th. Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Barclays reduced their price objective on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. Finally, Guggenheim reissued a “buy” rating and issued a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $50.40.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $30.82 on Friday. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The business’s 50-day moving average price is $38.63 and its 200 day moving average price is $43.66. Twist Bioscience Co. has a 52-week low of $30.72 and a 52-week high of $60.90. The firm has a market cap of $1.85 billion, a P/E ratio of -9.12 and a beta of 2.54.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). The business had revenue of $92.79 million during the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. As a group, sell-side analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In related news, COO Patrick John Finn sold 2,058 shares of the firm’s stock in a transaction that occurred on Wednesday, April 23rd. The shares were sold at an average price of $39.99, for a total value of $82,299.42. Following the completion of the transaction, the chief operating officer now owns 265,460 shares of the company’s stock, valued at approximately $10,615,745.40. This trade represents a 0.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Paula Green sold 918 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $37,555.38. Following the completion of the sale, the senior vice president now directly owns 130,912 shares of the company’s stock, valued at approximately $5,355,609.92. This trade represents a 0.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,991 shares of company stock valued at $742,654 over the last three months. Company insiders own 3.01% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.